Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Calgary
$120,000.00
The Epidemiology, Management, and Prevention of Chronic Kidney Disease in Transgender Individuals
EF 2024-25
Résumé
The transgender population in Canada (sex assigned at birth differs from their gender identity) includes approximately 100,000 individuals. Transgender individuals experience higher rates of chronic diseases and mortality compared to their cisgender peers (sex assigned at birth aligns with their gender identity). Chronic kidney disease (CKD) has been declared a global public health issue. It is also a leading cause of death in Canada, which has placed a significant burden on our healthcare system. There is a lack of research aimed at understanding the impacts of CKD in the transgender community, resulting in gaps in knowledge about their specific risk factors, care needs, and effective management strategies. Therefore, this research program, which is addressing a community identified priority, aims to explore CKD in transgender individuals, with a specific focus on the epidemiology, management, and prevention of this disease. First, I will explore how widespread CKD is and how often it occurs in transgender people. Next, I will investigate potential differences in how medical care is provided to transgender and cisgender individuals living with CKD. Finally, I aim to explore optimal levels of testosterone and estrogen in circulation (resulting from testosterone and estrogen therapy use) that promote gender-affirming goals, while optimizing blood pressure (an important risk factor for CKD). The transgender population is growing, yet remains medically underserved in Canada. Despite a potentially elevated risk for CKD, no evidence-based interventions for risk reduction specific to the transgender population exist to-date. The results of this patient-partnered work will directly inform shared-decision making regarding kidney disease risk, prevention, and management between patients and care providers such that healthcare inequities can be addressed.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518122
Name
Pattar Badal S
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
The Epidemiology, Management, and Prevention of Chronic Kidney Disease in Transgender Individuals
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Blood Pressure; Chronic Kidney Disease; Disease Management; Disease Prevention; Epidemiology; Estrogen; Gender-Affirming Hormone Therapy; Sex And Gender+ Science; Testosterone; Transgender Health
Abstract
The transgender population in Canada (sex assigned at birth differs from their gender identity) includes approximately 100,000 individuals. Transgender individuals experience higher rates of chronic diseases and mortality compared to their cisgender peers (sex assigned at birth aligns with their gender identity). Chronic kidney disease (CKD) has been declared a global public health issue. It is also a leading cause of death in Canada, which has placed a significant burden on our healthcare system. There is a lack of research aimed at understanding the impacts of CKD in the transgender community, resulting in gaps in knowledge about their specific risk factors, care needs, and effective management strategies. Therefore, this research program, which is addressing a community identified priority, aims to explore CKD in transgender individuals, with a specific focus on the epidemiology, management, and prevention of this disease. First, I will explore how widespread CKD is and how often it occurs in transgender people. Next, I will investigate potential differences in how medical care is provided to transgender and cisgender individuals living with CKD. Finally, I aim to explore optimal levels of testosterone and estrogen in circulation (resulting from testosterone and estrogen therapy use) that promote gender-affirming goals, while optimizing blood pressure (an important risk factor for CKD). The transgender population is growing, yet remains medically underserved in Canada. Despite a potentially elevated risk for CKD, no evidence-based interventions for risk reduction specific to the transgender population exist to-date. The results of this patient-partnered work will directly inform shared-decision making regarding kidney disease risk, prevention, and management between patients and care providers such that healthcare inequities can be addressed.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Pattar, Badal S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~